CN119212685A - 用于活性成分改良释放的组合物 - Google Patents

用于活性成分改良释放的组合物 Download PDF

Info

Publication number
CN119212685A
CN119212685A CN202380035252.5A CN202380035252A CN119212685A CN 119212685 A CN119212685 A CN 119212685A CN 202380035252 A CN202380035252 A CN 202380035252A CN 119212685 A CN119212685 A CN 119212685A
Authority
CN
China
Prior art keywords
composition
hpmc
active ingredient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380035252.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·古普塔
D·巴尔-沙洛姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prole Life Products Co
Original Assignee
Prole Life Products Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prole Life Products Co filed Critical Prole Life Products Co
Publication of CN119212685A publication Critical patent/CN119212685A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380035252.5A 2022-04-22 2023-04-20 用于活性成分改良释放的组合物 Pending CN119212685A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22169513.3 2022-04-22
EP22169513 2022-04-22
EP22209460.9 2022-11-24
EP22209460 2022-11-24
PCT/EP2023/060373 WO2023203173A1 (en) 2022-04-22 2023-04-20 Compositions for modified release of active ingredients

Publications (1)

Publication Number Publication Date
CN119212685A true CN119212685A (zh) 2024-12-27

Family

ID=86328542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380035252.5A Pending CN119212685A (zh) 2022-04-22 2023-04-20 用于活性成分改良释放的组合物

Country Status (9)

Country Link
US (1) US20250262160A1 (https=)
EP (1) EP4511009A1 (https=)
JP (1) JP2025513255A (https=)
KR (1) KR20250002580A (https=)
CN (1) CN119212685A (https=)
CA (1) CA3249641A1 (https=)
IL (1) IL316428A (https=)
MX (1) MX2024012984A (https=)
WO (1) WO2023203173A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US9526701B2 (en) 2011-12-20 2016-12-27 Keith R. Latham Sustained drug release and improved product stability using non-covalent particle coating methods
EP4090313B1 (en) * 2020-01-13 2024-03-13 Amneal Complex Products Research LLC Sustained release compositions comprising liothyronine

Also Published As

Publication number Publication date
US20250262160A1 (en) 2025-08-21
EP4511009A1 (en) 2025-02-26
IL316428A (en) 2024-12-01
CA3249641A1 (en) 2023-10-26
JP2025513255A (ja) 2025-04-24
KR20250002580A (ko) 2025-01-07
MX2024012984A (es) 2024-12-06
WO2023203173A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
FI113336B (fi) Menetelmä tramadolisuolaa sisältävän lääkeaineen valmistamiseksi, jolla on viivästynyt vaikuttavan aineen vapautuminen
Nayak et al. Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system
MX2011005042A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
JP2016528302A (ja) 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
RS52057B (sr) Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
JP2001519379A (ja) 遅延性総放出胃腸薬物送達システム
CN115089556A (zh) 利那洛肽的延迟释放组合物
CA2850468A1 (en) Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US20170239203A1 (en) Pregabalin sustained-release preparation
Higton The pharmaceutics of ibuprofen
BRPI0619384A2 (pt) comprimido de neramexano com matriz de liberação modificada
KR20130030260A (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
WO2020227437A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
CN104997748B (zh) 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺
CA2533330A1 (en) Pharmaceutical preparation containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
KR20250134143A (ko) 골관절염과 같은 관절 질환의 치료에서 사용하기 위한 콜키신을 포함하는 관절내 주사용 제형
RU2336863C2 (ru) Препараты в виде пеллет сферической формы
DE60319983T2 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
CA2470377A1 (fr) Forme galenique solide pour l&#39;administration oculaire de principe actif, insert ophtalmique solide et soluble et procede de fabrication d&#39;un tel insert
CN119212685A (zh) 用于活性成分改良释放的组合物
EP2801350B1 (en) Pharmaceutical Formulations of Lacosamide
JPWO2017146052A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
RU2411035C2 (ru) Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината
TW201626990A (zh) 含有褪黑激素和舍曲林的口服複合錠劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination